| Method of making induced pluripotent stem cells using p53 inhibitors S Yamanaka, K Takahashi, K Okita US Patent 12,012,615, 2024 | | 2024 |
| Selective Translation Orchestrates Key Signaling Pathways in Primed Pluripotency C Okubo, M Nakamura, M Sato, Y Shichino, M Mito, Y Takashima, ... bioRxiv, 2024.02. 09.579580, 2024 | | 2024 |
| Ryosuke Hayasaka1, 2, Sho Tabata3, Masako Hasebe1, Satsuki Ikeda1, Tomoya Hikita4, Chitose Oneyama4, 5, 6, 7, Jun Yoshitake7, Daisuke Onoshima7, Kumiko Takahashi8, Takahiro … R Hayasaka, S Tabata, M Hasebe, S Ikeda, T Hikita, C Oneyama, ... | | 2023 |
| Improved Sendai viral system for reprogramming to naive pluripotency A Kunitomi, R Hirohata, V Arreola, M Osawa, TM Kato, M Nomura, ... Cell Reports Methods 2 (11), 2022 | 19 | 2022 |
| Exocyst complex component 2 is a potential host factor for SARS-CoV-2 infection R Yi, R Hashimoto, A Sakamoto, Y Matsumura, M Nagao, K Takahashi, ... Iscience 25 (11), 2022 | 5 | 2022 |
| Multi-omics approach reveals posttranscriptionally regulated genes are essential for human pluripotent stem cells M Iwasaki, Y Kawahara, C Okubo, T Yamakawa, M Nakamura, T Tabata, ... Iscience 25 (5), 2022 | 5 | 2022 |
| A stress-reduced passaging technique improves the viability of human pluripotent cells K Takahashi, C Okubo, M Nakamura, M Iwasaki, Y Kawahara, T Tabata, ... Cell reports methods 2 (2), 2022 | 6 | 2022 |
| Nuclear reprogramming factor and induced pluripotent stem cells S Yamanaka, K Takahashi, M Nakagawa US Patent App. 17/445,282, 2022 | | 2022 |
| Dual inhibition of TMPRSS2 and Cathepsin B prevents SARS-CoV-2 infection in iPS cells R Hashimoto, A Sakamoto, S Deguchi, R Yi, E Sano, A Hotta, ... Molecular Therapy-Nucleic Acids 26, 1107-1114, 2021 | 50 | 2021 |
| Post-transcriptionally regulated genes are essential for pluripotent stem cell survival M Iwasaki, Y Kawahara, T Tabata, Y Nishi, M Narita, A Ohta, H Saito, ... bioRxiv, 2021.10. 18.462967, 2021 | | 2021 |
| The pluripotent stem cell-specific transcript ESRG is dispensable for human pluripotency K Takahashi, M Nakamura, C Okubo, Z Kliesmete, M Ohnuki, M Narita, ... PLoS genetics 17 (5), e1009587, 2021 | 20 | 2021 |
| Critical roles of translation initiation and RNA uridylation in endogenous retroviral expression and neural differentiation in pluripotent stem cells K Takahashi, D Jeong, S Wang, M Narita, X Jin, M Iwasaki, SD Perli, ... Cell reports 31 (9), 2020 | 19 | 2020 |
| Temperature-dependent valence state within the metallic phase of probed by hard x-ray photoelectron spectroscopy S Dash, M Okawa, T Kajita, T Yoshino, R Shimoyama, K Takahashi, ... Physical Review B 99 (3), 035122, 2019 | 6 | 2019 |
| Induced pluripotent stem cells and their use in human models of disease and development P Karagiannis, K Takahashi, M Saito, Y Yoshida, K Okita, A Watanabe, ... Physiological reviews 99 (1), 79-114, 2019 | 320 | 2019 |
| Nuclear reprogramming factor and induced pluripotent stem cells S Yamanaka, K Takahashi, M Nakagawa US Patent App. 15/474,855, 2018 | | 2018 |
| Method of efficiently establishing induced pluripotent stem cells K Takahashi, K Tanabe, S Yamanaka US Patent 10,077,429, 2018 | 1 | 2018 |
| Assessment of established techniques to determine developmental and malignant potential of human pluripotent stem cells Nature communications 9 (1), 1925, 2018 | 96 | 2018 |
| Method for screening induced pluripotent stem cells S Yamanaka, K Takahashi, M Koyanagi, M Ohnuki US Patent 9,938,585, 2018 | | 2018 |
| MYC releases early reprogrammed human cells from proliferation pause via retinoblastoma protein inhibition TA Rand, K Sutou, K Tanabe, D Jeong, M Nomura, F Kitaoka, E Tomoda, ... Cell reports 23 (2), 361-375, 2018 | 32 | 2018 |
| Method of efficiently establishing induced pluripotent stem cells S Yamanaka, K Takahashi, K Okita | | 2017 |